ARG-007 Prevents Uptake & Aggregation of Key Protein
Filed with ASX · · 6 pages · English
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Investor Presentation
- ARG-007 Phase 2 Clinical Trial Update
- ARG-007 Protects Brain Cells in Moderate TBI Model
- Argenica Successfully Completes $4.0m Placement
- Final Phase1 Clinical Trial Report
Later from Argenica Therapeutics
- Response to ASX Aware Query
- Appendix 4E & Annual Report 30 June 2023
- Positive FDA Feedback Following Pre-Ind Meeting
- Grant Awarded To Develop Additional Administration Route
- Ethics Approval Received for Phase 2 Trial
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics